http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 November 12, 2009 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and... http://pharmalicensing.com/redirs/news_rss//public/news/view/499900/0/12/champions-biotechnology-to-present-data-at-aacr-eortc-2009-regarding-the-predictability-of-biomerk-tumorgraft-tm-platform-to-guide-personalized-cancer-treatment-and-accelerate-oncology-drug-development http://pharmalicensing.com/redirs/news_rss//public/news/view/499900/0/12/champions-biotechnology-to-present-data-at-aacr-eortc-2009-regarding-the-predictability-of-biomerk-tumorgraft-tm-platform-to-guide-personalized-cancer-treatment-and-accelerate-oncology-drug-development NEWTON, Mass., November 12, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that... http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/12/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/12/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement FARMINGDALE, N.Y., November 12, 2009 -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and... http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/0/12/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/0/12/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries NORWALK, CT, November 11, 2009 - IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS... http://pharmalicensing.com/redirs/news_rss//public/news/view/499769/0/12/ims-health-to-launch-oncology-quantifier-delivering-integrated-insights-for-enhanced-market-measurement-commercial-strategies http://pharmalicensing.com/redirs/news_rss//public/news/view/499769/0/12/ims-health-to-launch-oncology-quantifier-delivering-integrated-insights-for-enhanced-market-measurement-commercial-strategies November 11, 2009--A recent paper, by researchers at Genentech, describes the preclinical evaluation of the pharmacokinetic properties of GDC-0449, a potent selective Hedgehog signalling pathway... http://pharmalicensing.com/redirs/news_rss//public/news/view/499713/0/12/simcyp-simulator-aids-in-preclinical-adme-assessment-of-genentech-compound http://pharmalicensing.com/redirs/news_rss//public/news/view/499713/0/12/simcyp-simulator-aids-in-preclinical-adme-assessment-of-genentech-compound November 11, 2009 -- Nippon Kayaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Koichiro Shimada) concluded the agreement on apaziquone (generic name) for non-muscle invasive bladder... http://pharmalicensing.com/redirs/news_rss//public/news/view/499715/0/12/conclusion-of-the-agreement-on-apaziquone-for-non-muscle-invasive-bladder-cancer http://pharmalicensing.com/redirs/news_rss//public/news/view/499715/0/12/conclusion-of-the-agreement-on-apaziquone-for-non-muscle-invasive-bladder-cancer Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/0/12/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/0/12/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma MISSISSAUGA, ON, Nov. 11, 2009- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related... http://pharmalicensing.com/redirs/news_rss//public/news/view/499741/0/12/ym-biosciences-reports-fiscal-first-quarter-2010-operational-and-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499741/0/12/ym-biosciences-reports-fiscal-first-quarter-2010-operational-and-financial-results Basel, Switzerland, 10 November 2009 - Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody ArzerraTM, which has just been approved for use in patients with chronic lymphocytic leukemia... http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/0/12/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/0/12/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab CARLSBAD, Calif.-- November 10, 2009-- The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research... http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/12/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/12/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom